NO986100L - Androgene reseptormodulerende forbindelser og fremgangsmÕter - Google Patents

Androgene reseptormodulerende forbindelser og fremgangsmÕter

Info

Publication number
NO986100L
NO986100L NO986100A NO986100A NO986100L NO 986100 L NO986100 L NO 986100L NO 986100 A NO986100 A NO 986100A NO 986100 A NO986100 A NO 986100A NO 986100 L NO986100 L NO 986100L
Authority
NO
Norway
Prior art keywords
compounds
androgen receptor
methods
disclosed
modulating compounds
Prior art date
Application number
NO986100A
Other languages
English (en)
Other versions
NO311645B1 (no
NO986100D0 (no
Inventor
James P Edwards
Robert Huguchi
Todd Jones
Original Assignee
Ligand Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceutical Inc filed Critical Ligand Pharmaceutical Inc
Publication of NO986100L publication Critical patent/NO986100L/no
Publication of NO986100D0 publication Critical patent/NO986100D0/no
Publication of NO311645B1 publication Critical patent/NO311645B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
NO19986100A 1996-06-27 1998-12-23 Androgene reseptormodulerende forbindelser NO311645B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2199796P 1996-06-27 1996-06-27
PCT/US1997/011222 WO1997049709A1 (en) 1996-06-27 1997-06-26 Androgen receptor modulator compounds and methods

Publications (3)

Publication Number Publication Date
NO986100L true NO986100L (no) 1998-12-23
NO986100D0 NO986100D0 (no) 1998-12-23
NO311645B1 NO311645B1 (no) 2001-12-27

Family

ID=21807289

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19986100A NO311645B1 (no) 1996-06-27 1998-12-23 Androgene reseptormodulerende forbindelser

Country Status (12)

Country Link
EP (1) EP0918774B9 (no)
JP (1) JP2000513362A (no)
AT (1) ATE209207T1 (no)
AU (1) AU728178B2 (no)
BR (1) BR9710988A (no)
DE (1) DE69709752T2 (no)
DK (1) DK0918774T3 (no)
ES (1) ES2168650T3 (no)
NO (1) NO311645B1 (no)
PT (1) PT918774E (no)
RU (1) RU2214412C2 (no)
WO (1) WO1997049709A1 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7003304B1 (en) 1997-09-19 2006-02-21 Thompson Investment Group, Llc Paging transceivers and methods for selectively retrieving messages
US6636733B1 (en) 1997-09-19 2003-10-21 Thompson Trust Wireless messaging method
US6826407B1 (en) 1999-03-29 2004-11-30 Richard J. Helferich System and method for integrating audio and visual messaging
US6253061B1 (en) 1997-09-19 2001-06-26 Richard J. Helferich Systems and methods for delivering information to a transmitting and receiving device
US6983138B1 (en) 1997-12-12 2006-01-03 Richard J. Helferich User interface for message access
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
MXPA02002032A (es) * 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
US6593493B1 (en) 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
WO2001059448A1 (fr) * 2000-02-10 2001-08-16 Chugai Seiyaku Kabushiki Kaisha Procede de criblage d'un agent antiandrogene
WO2002000653A2 (en) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Fused cyclic compounds as modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
AU2001267904A1 (en) 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Novel antiandrogenic agent
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
IL155019A0 (en) * 2000-09-19 2003-10-31 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
WO2003034987A2 (en) * 2001-10-19 2003-05-01 Merck & Co., Inc. Androgen receptor modulators and methods of use thereof
US7087636B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
CA2471754A1 (en) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Androgen receptor antagonist
JP5113979B2 (ja) 2002-02-28 2013-01-09 ユニバーシティ オブ テネシー リサーチ ファウンデーション 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法
US6858621B2 (en) 2002-04-26 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CA2511089A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
BRPI0413820A (pt) 2003-08-22 2006-10-24 Ligand Pharm Inc derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
AU2007212191B2 (en) * 2006-02-10 2011-12-22 Janssen Pharmaceutica N.V. Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
RU2381229C2 (ru) * 2007-10-17 2010-02-10 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 11b-(ГEТ)АРИЛ-2,3,6,11b-ТЕТРАГИДРООКСАЗОЛО[2',3':2,1]ПИРРОЛО[3,4-b]ХИНОЛИН-5,11-ДИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
AR076524A1 (es) * 2009-04-30 2011-06-15 Nissan Chemical Ind Ltd Forma cristalina de un compuesto de benzopirano triciclico y metodo de produccion de la misma
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス,インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
CA2824521C (en) 2011-01-20 2016-06-28 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and related methods
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用
CN106565723B (zh) * 2016-11-04 2019-08-27 江苏师范大学 一种呋喃并吡啶、苯并吡啶类衍生化合物的制备方法
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN116969959B (zh) * 2023-08-03 2025-10-31 浙江大学 取代四氢喹啉类衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2959839B2 (ja) * 1989-07-07 1999-10-06 アンドルシェルシュ・インコーポレイテッド 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
DK0540099T3 (da) * 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
US5677336A (en) * 1993-10-21 1997-10-14 Ligand Pharmaceuticals Incorporated Non-steroid androgen receptor antagonist compounds and methods
AU717251B2 (en) * 1994-12-22 2000-03-23 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods

Also Published As

Publication number Publication date
RU2214412C2 (ru) 2003-10-20
JP2000513362A (ja) 2000-10-10
NO311645B1 (no) 2001-12-27
DE69709752T2 (de) 2002-07-18
DK0918774T3 (da) 2002-05-21
AU3508497A (en) 1998-01-14
ES2168650T3 (es) 2002-06-16
ATE209207T1 (de) 2001-12-15
BR9710988A (pt) 2002-01-15
EP0918774B9 (en) 2002-04-10
PT918774E (pt) 2002-05-31
NO986100D0 (no) 1998-12-23
WO1997049709A1 (en) 1997-12-31
EP0918774B1 (en) 2001-11-21
EP0918774A1 (en) 1999-06-02
DE69709752D1 (de) 2002-02-21
AU728178B2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
NO986100D0 (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
DE69531403D1 (de) Allosterische modulatoren des nmda-rezeptors
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
DK0873295T3 (da) Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
YU7797A (sh) Kombinovana terapija za osteoporozu
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
AP9801269A0 (en) Prostaglandin agonists.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DK0874625T3 (da) Indanderivater til antipsykotiske præparater
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
AU7216498A (en) Inhibitors of the urokinase receptor
DE69718146D1 (de) At1 rezeptor antagonist zur anregung von apoptosis
CA2259031A1 (en) Androgen receptor modulator compounds and methods
UA29457C2 (uk) Лікувальне покриття